Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers May 28, 2016
Pharmacy Choice - News - U.S. Pharmaceutical Industry - May 28, 2016

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

5/28/16 - "Use of a Thiazolo Pyrimidinone for the Treatment of Inflammatory Bowel Disease" in Patent Application Approval Process (USPTO 20160120801)
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week A patent application by the inventors DUTT, Chaitanya; CHAUTHAIWALE, Vijay; GUPTA, Ram; ZAMBAD, Shitalkumar; DESHPANDE, Shailesh; KOTECHA, Jignesh; GUPTA, Ramesh; SRIVASTAVA, Sanjay; CHHIPA, Laxmikant; ABRAHAM, Jaya, filed on May 12, 2014, was made available online on May 12,
5/28/16 - AbbVie, Biogen: FDA Approves Once-Monthly ZINBRYTA For Multiple Sclerosis
WESTON- AbbVie, a research-based biopharmaceutical company, and Biogen late Friday announced that the U.S. Food and Drug Administration or FDA approved ZINBRYTA, a new once-monthly, self-administered, subcutaneous treatment for relapsing forms of multiple sclerosis or RMS. The FDA approval of ZINBRYTA is primarily based on results from two clinical
5/28/16 - ASTRAZENECA'S FASLODEX MET PRIMARY ENDPOINT IN FIRST-LINE TREATMENT OF ADVANCED BREAST CANCER [tayyar.org (Lebanon)]
-AstraZeneca today announced positive results from the Phase III FALCON trial. Sean Bohen, Executive Vice President, Global Medicines Development and Chief. Medical Officer at AstraZeneca, said: "The FALCON results bring us closer to.
5/28/16 - BioDelivery Sciences and Collegium Pharmaceutical Announce the Signing of a Licensing Agreement for ONSOLIS in the U.S.
By a News Reporter-Staff News Editor at Marketing Weekly News BioDelivery Sciences International, Inc. and Collegium Pharmaceutical, Inc. announced the signing of a licensing agreement under which BDSI is granting the exclusive rights to develop and commercialize ONSOLIS in the U.S. to Collegium. Under terms of the agreement, Collegium will be...
5/28/16 - Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA? (Daclizumab) for Multiple Sclerosis
CAMBRIDGE, Mass.& NORTH CHICAGO, Ill. The U.S. Food and Drug Administration approved ZINBRYTA TM, a new once-monthly, self-administered, subcutaneous treatment for relapsing forms of multiple sclerosis, Biogen and AbbVie announced today. Clinical data showed ZINBRYTA significantly reduced relapses and brain lesions for up to three years compare
5/28/16 - FDA Grants Accelerated Approval to Ocaliva? (Obeticholic Acid) for the Treatment of Patients with PBC
Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that the U.S. Food and Drug Administration has granted accelerated approval to Ocaliva for the treatment of primary biliary cholangitis, previously know
5/28/16 - Generics maker Sawai Pharma prepares to tap US market [Seven Days (United Arab Emirates)]
Sawai Pharmaceutical is gearing up to sell generic drugs in the U.S., carrying out a strategy shift that makes the huge American market a central pillar of the company's long-term growth plans. The U.S. generic-drug market is estimated at $91 billion, 10 times the annual market in Japan. The company intends to formulate pitavastatin and the three o
5/28/16 - Highland Therapeutics Announces Appointment of Craig S. Lewis as President
By a News Reporter-Staff News Editor at Marketing Weekly News Highland Therapeutics Inc. announced that its U.S. subsidiary, Ironshore Pharmaceuticals Inc., has appointed Craig S. Lewis to the position of President, reporting directly to the IPA Board of Directors. Prior to that, Mr. Lewis served as the Senior Vice President, Global Business Insi
5/28/16 - Japan : Chugais Bispecific Antibody ACE910/Emicizumab Phase l Data in Patients with Hemophilia A Published in The New England Journal Of Medicine... [TendersInfo (India)]
Chugai Pharmaceutical Co., Ltd. announced today that the data from hemophilia A patients who participated in a Phase I study of the bispecific antibody emicizumab was published online in The New England Journal of Medicine on May 25, 2016. The study results had been presented at the 56th American Society of Hematology Annual Meeting held in San Fra
5/28/16 - NuvOx Pharma Awarded STTR Grant from NCI for Ultrasound Contrast Agent to Diagnose Pancreatic Cancer
Evan Unger, MD, President and CEO of NuvOx Pharma, a Tucson based biotechnology company, announced that the company has been awarded a grant from the National Cancer Institute to develop an ultrasound contrast agent to diagnose pancreatic cancer. The Phase I Small Business Technology Transfer grant is a joint development project between NuvOx and
5/28/16 - Triangle pharma wizards put $49M to work [Daily Star, The (Lebanon)]
Its the latest in a string of drug development companies co-founded by Butts, this time with partners Bill Wofford, Michael Ackermann, Ph.D., MBA, and Stanford University sleep specialist Jed Black, M.D. Then, a few short years after starting Aerial, the founders sold the companys clinical-stage narcolepsy drug to Ireland- based Jazz Pharmaceutical
5/28/16 - United States : ABL & REGENXBIO to team up on RGX-501 manufacturing for human clinical trials [TendersInfo (India)]
The leading global contract research and manufacturing firm ABL, Inc. has made an announcement on its settlement of deals with the major biotechnology sector player Regenxbio, Inc., for the production of its lead product RGX-501 intended for clinical trials on human beings. The ABL President& CEO Thomas VanCott, Ph.D. revealed, We are delighted to
5/27/16 - "Cadotril Particles" in Patent Application Approval Process (USPTO 20160120834)
By a News Reporter-Staff News Editor at Health& Medicine Week A patent application by the inventors Bagchi, Saumitra; Vuppala, Murali K., filed on October 29, 2015, was made available online on May 12, 2016, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assigned to a
5/27/16 - "Pharmaceutical Composition for Treating Disease Associated with Demyelination of Neurons and Method of Using the Pharmaceutical Composition" in...
"Pharmaceutical Composition for Treating Disease Associated with Demyelination of Neurons and Method of Using the Pharmaceutical Composition" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Lee, Yunil; Chang, Kiyoung; Park, Sangchul; Cho, Sungchun, filed on November 5
5/27/16 - "Pharmaceutical Formulations Comprising Incretin Mimetic Peptide and Aprotic Polar Solvent" in Patent Application Approval Process (USPTO 20160120950)
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Jennings, Robert N.; Ong, John T.H.; Rhodes, Christopher A.; Stetsko, Gregg; Prestrelski, Steven J., filed on October 30, 2015, was made available online on May 12, 2016, according to news reporting originating from Washington, D.C., by NewsRx correspondents.
5/27/16 - 4/26 Workshop on COAs in Cancer Clinical Trials
By a News Reporter-Staff News Editor at Drug Week The Food and Drug Administration's Office of Hematology and Oncology Products, in co-sponsorship with the Critical Path Institute's Patient-Reported Outcome Consortium, is holding a public meeting titled "Workshop on Clinical Outcome Assessments in Cancer Clinical Trials" on Tuesday, April 26, 7:3
5/27/16 - AbbVie's HUMIRA (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of Non-Infectious Uveitis, a Disease that Can Severely Impact Vision[1]
AbbVie, a global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion for HUMIRA for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids or in
5/27/16 - Aclaris Therapeutics Announces $20.0 Million Private Placement
MALVERN, Pa., May 27, 2016 Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, announced today that it has entered into a stock purchase agreement with a group of institutional accredited investors for the private placement of 1,081,082 shares of common stock at a purchase price of $18.50 per share, yielding expected g
5/27/16 - Amgen Receives Positive CHMP Opinion To Extend Indication Of Kyprolis (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma
Amgen today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion to extend the current indication for Kyprolis to include treatment in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy.
5/27/16 - Ampio Launches Clinical Trial of AMPION for the Treatment of Osteoarthritis of the Hand
By a News Reporter-Staff News Editor at Health& Medicine Week Ampio Pharmaceuticals, Inc. announced that patient dosing has begun in the initial clinical trial of Ampion? for the treatment of pain due to osteoarthritis of the hand. Michael Macaluso, Ampio's CEO, noted: "The World Health Organization has determined that Osteoarthritis will be th
5/27/16 - ASTRAZENECA'S FASLODEX MET PRIMARY ENDPOINT IN FIRST-LINE TREATMENT OF ADVANCED BREAST CANCER
AstraZeneca today announced positive results from the Phase III FALCON trial comparing Faslodex 500 mg to Arimidex 1 mg for the treatment of locally-advanced or metastatic breast cancer, in post-menopausal women who have not had prior hormonal treatment for hormone-receptor-positive breast cancer. Sean Bohen, Executive Vice President, Global...
5/27/16 - AstraZeneca's Fulvestrant Met Its Primary Endpoint as First-Line Treatment in a Phase III Trial for HR+ Advanced Breast Cancer
AstraZeneca today announced positive results from the Phase III FALCON trial comparing fulvestrant 500 mg to anastrozole 1 mg for the treatment of locally-advanced or metastatic breast cancer, in postmenopausal women who have not had prior hormonal treatment for hormone receptor positive breast cancer. 1. Fulvestrant 500 mg demonstrated superiority
5/27/16 - Australia,United States : Victorias Best Biotech minds off to the US [TendersInfo (India)]
Victoria is a world-leading location for the development and manufacture of medical technologies, biotechnologies and pharmaceuticals with one-third of Australian clinical trials activity taking place in Victoria. Victoria is also home to more than 180 biotech companies, ten major medical research institutes, ten major teaching hospitals and nine..
5/27/16 - Aviragen Therapeutics Provides Update on Phase 2a Trial of BTA585 for the Treatment of RSV Infections [National News Agency (Lebanon)]
-Aviragen Therapeutics, Inc., a pharmaceutical company that is developing the next generation of antivirals, today announced that it has voluntarily decided to delay further enrollment in the Phase 2 a trial of BTA585 for the treatment of RSV infections being conducted in the U.K. This decision emanated from a lab report from one subject showing an
5/27/16 - Berry Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., May 27 Berry Pharmaceuticals, Georgetown, Texas, has been assigned a patent developed by Don Wayne Berry, Georgetown, Texas, for a "topical treatment of keratotic lesions using hamelia patens." The patent application was filed on Feb. 12, 2014. Written by Kusum Sangma; edited by Jaya Anand.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415